


Fenfluramine & Phentermine Analyzed with HPLC - AppNote

Assay for Anti-Obesity Combination Capsule & Tablet

This Application Note illustrates Separation of similar compounds in the Phenethylamine class of compounds; Fenfluramine & Phentermine.

These two compounds in particular were once used as APIs in the same formulation. The data shows how these Phenethylamines can be easily Retained and Separated with an Isocratic Mobile Phase that is LCMS compatible and easy to prepare. Data from two lots is shown to illustrate the Reproducibility of the Method.



Peak:

- 1. Fenfluramine
- 2. Phentermine

Method Conditions

Column: Cogent Diamond Hydride™, 4µm, 100Å

Catalog No.: 70000-7.5P Dimensions: 4.6 x 75mm

Mobile Phase: 25:75 DI Water / Acetonitrile with 0.1% Formic Acid (v/v)

Injection vol.: 1µL

Flow rate: 1.0mL / minute Detection: UV @ 210nm

Sample Preparation: 30mg strength Ionamin® capsule contents were added to a 25mL volumetric flask. A portion of mobile phase diluent was added and the flask was sonicated for 10 minutes. It was

then diluted to mark, mixed, and filtered with a 0.45µm Nylon Syringe Filter (MicroSolv Tech Corp.). 20mg strength Pondimin® Tablet was ground and added to another 25mL volumetric flask. A filtrate was obtained in the same manner as with lonamin®, and the two filtrates were mixed 1:1. Individual extracts were used for peak identity confirmation.

to: 0.9 minutes

Note: Fenfluramine and Phentermine were once sold as an anti-obesity medication, however, Fenfluramine was shown to produce serious side effects of pulmonary hypertension and heart valve problems. Phentermine does not produce these side effects.



Attachment

No 239 Fenfluramine and Phentermine Analyzed with HPLC pdf 0.4 Mb Download File

Printed from the Chrom Resource Center
Copyright 2025, All Rights Apply
MicroSolv Technology Corporation
9158 Industrial Blvd. NE, Leland, NC 28451

Tel: (732) 380-8900 Fax: (910) 769-9435

Email: customers@mtc-usa.com

Website: www.mtc-usa.com